Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has announced a proposed rights issue to raise up to NOK 50 million, with strong support from existing shareholders, including presubscription commitments totaling NOK 24.2 million. This capital injection will provide the company with a twelve-month cash runway to achieve significant pre-clinical development milestones and advance its gene and cell therapy programs, enhancing its industry positioning and stakeholder value.
More about Targovax ASA
Circio Holding ASA is a biotechnology company based in Oslo, Norway, specializing in developing novel circular RNA expression technology for gene and cell therapy. The company focuses on advancing its circVec circular RNA expression platform and has recently engaged in a feasibility study with a major global pharmaceutical company.
YTD Price Performance: 77.75%
Average Trading Volume: 4,530,369
Current Market Cap: NOK181.3M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.